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Available online 27 November 2015Themolecular mechanisms responsible for opposing oncogenic and tumor-suppressor activities of NF-kB are ob-
scure. Semi-quantitative immunohistochemistry of primary breast tumors using antibodies to RelA, the pleiotro-
pic NF-kB factor, and Ki67 revealed a negative correlation between RelA levels and Ki67-index among ER+/
HER2− tumors [1]. Similarly, expression of AURKA, amarker for proliferation, negatively correlateswith expres-
sion of NFKBIA, a surrogate for RelA expression and activity, in ER+/HER2− tumors analyzed by The Cancer
Genome Atlas [2–4]. Furthermore, conditional expression of RelA using a Tetracycline-inducible system in Human
Mammary Epithelial Cells (HRA cells) caused proliferation arrest while withdrawal of Doxycycline (Dox) and sup-
pression of RelA expression in arrested cells restored cell cycle progression [1]. To identify genes responsible for
the negative relationship between RelA levels and proliferation, we performed genome-wide gene expression anal-
ysis of HRA cells under the following conditions: RelA un-induced, NoDox (ND); Dox induced for 24 h; Dox induced
for 72 h; Dox induced for 24 h thenDoxwithdrawn for 48 h. The expression datawas submitted to Gene Expression
Ominibus (GEO) and the accession number is GSE65040. Analysis of the data identiﬁed cross-talk between basal
RelA activity and the Interferon pathwaymediated by IRF1, a target of RelA [5]. Activation of the Interferon pathway
lead to down-regulation of CDK4 expression resulting in RB1 hypo-phosphorylation and suppression of cell cycle
progression. The tumor-suppressor activity of NF-kB, speciﬁcally RelA,may stem from cross-talkwith the Interferon
pathway.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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. This is an open access article under2. Materials, methods and experimental design
2.1. Materials
Late passage P16neg hTERT immortalized HumanMammary Epithelial
Cells (HMEC) were a gift from Jean Zhao [6]. The cells were cultured in
DMEM-F12 (Life Technologies) supplemented with Insulin (10 μg/ml;
Life Technologies), Epidermal Growth Factor (10 ng/ml, Peprotech),
Cholera Toxin (1 ng/ml, Sigma Aldrich), Hydrocortisone (500 ng/ml,
Sigma-Aldrich) and 0.6% FBS (Clontech Laboratories). Phoenix cells
(Orbigen) were cultured in DMEM supplemented with 10% FBS
(Clontech). Other chemicals used in the study were: Anti-Anti (Life
Technologies) Doxycycline (Sigma-Aldrich), Neomycin (Sigma Aldrich),
Puromycin (Invivogen), andmiRNeasymini kit (Qiagen). The PrimeView
Human Gene Expression Array from Affymetrix was used to estimate
genome-wide gene expression levels.
2.2. Methods
Retroviruses encoding the Tetracycline promoter transactivator
(neomycin selection) and Flag-tagged RelA (Puromycin selection)
were generated in Phoenix cells using standard protocols. HMEC werethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Schematic representation of Dox treatment ofHRA cells to regulate RelA expression.
Open boxes indicate the absence of Dox, blue boxes indicate the presence of Dox. Green
arrows indicate times at which Dox was added, black arrow indicates withdrawal of Dox
and red arrows indicate time at which each sample was harvested for RNA extraction.
The names of triplicate samples are given for each treatment condition.
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and Polybrene (5 μg/ml, Millipore) for 12 h. Infected HMECwere select-
ed usingNeomycin (400 μg/ml) and Puromycin (1 μg/ml). Resulting cell
line was designated HRA (HMEC harboring RelA) and pooled stable
cloneswere used in the experiment. Dox inducible (1 μg/ml) expression
of RelA and reduction of RelA expression after withdrawal of Dox were
conﬁrmed by Western blot [1].
HRA cells were plated in 6 well plates and 24 h later, treated with
Dox according to the scheme in Fig. 1 to generate triplicate samples
for gene expression analysis. ND (No Dox; un-treated samples) were
harvested 48, 72 and 96 h post-plating (indicated by red arrows in
Fig. 1). To generate the 24+ samples, independent samples were treat-
ed with Dox 24, 48 and 72 h post-plating (indicated by green arrows)
and harvested 24 h later (indicated by red arrows). The 72+ samples
were treated with Dox 24 h post plating (green arrow) and harvested
after 96 h of Dox treatment. The DW (Dox Withdrawn) sample was
generated by treating cells with Dox 24 h post plating (green arrow),
Dox withdrawn 24 h later (black arrow) and harvested after 48 h (red
arrow). Culturemedium in every platewas replacedwith freshmedium
containingDox or devoid of Dox as required 24 h post-plating and every
24 h thereafter. For harvesting total RNA, the plates were transferred to
ice, cells were washed with cold PBS and lysed using Trizol. Total RNA
was puriﬁed using the miRNeasy mini kit from Qiagen using the
manufacturer's protocol. The Affymetrix PrimeView array was used to
estimate gene expression. RNA labeling, hybridization and scanning
were performed at the Molecular Biology Core Facilities at Dana-
Farber Cancer Institute according to manufacturer's protocol.
2.3. Gene expression analysis
Quality checks of the expression data cel ﬁles were performed using
AffylmGUI in R and data from all arrays was conﬁrmed suitable fordownstream analysis [7]. The cel ﬁles were normalized using RMA in
GenePattern [8]. The Brainarray chip deﬁnition ﬁle (version 18) based
on ensemble gene (ENSG) was used for probe summarization [9].
Differentially expressed genes between pairs of sampleswere identiﬁed
using LIMMA implemented in MEV [10]. Other downstream analysis
performed using the dataset is described in a previous manuscript [1].
3. Conclusion
This dataset may be useful for identifying predictive biomarkers of
response to CDK4/6 inhibitors e.g. Palbociclib, Abemaciclib, LEE011
and P1446A-05 in RB1 competent tumors where CDK4 is not ampliﬁed
[11–14].
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